Dual GH Secretagogue Blend
A dual-peptide formulation combining CJC-1295 without DAC (a GHRH analog that stimulates GH production) with Ipamorelin (a selective growth hormone secretagogue that triggers GH release). The two peptides engage separate receptor pathways — GHRH receptor and GHS-R1a — to produce a synergistic effect on growth hormone output.
The CJC-1295/Ipamorelin blend is supplied as a lyophilized powder and reconstituted with bacteriostatic water. In research settings, it is typically administered via subcutaneous injection. The "without DAC" (Drug Affinity Complex) designation indicates that CJC-1295 in this formulation has a shorter half-life, producing more physiologically pulsatile GH patterns rather than sustained elevation.
The CJC-1295/Ipamorelin combination is one of the most widely studied dual-secretagogue protocols in the GH research space. By engaging both the GHRH receptor (production pathway) and the ghrelin receptor (release pathway), the combination is explored for potentially amplified GH output compared to either peptide alone. Researchers particularly value the selectivity of Ipamorelin, which does not significantly elevate cortisol, ACTH, or prolactin, making the combination suitable for studies seeking isolated GH axis activation.
For research purposes only. Not intended for consumption, clinical application, or diagnostic use.